StreetAlpha.app
Home › Stocks › BTMD

biote Corp. (BTMD)

$0.81
▼ −3.56%
LAST CLOSE · NOV 20

biote provides a training, software and marketing platform for clinics that treat hormone imbalance, and sells its own dietary supplements. It last closed at $0.81 on Nov 20, down 3.56% on the day. The next earnings report for BTMD is expected around Wed, Mar 10, 2027, after the close. For the quarter ended Sep 2026, BTMD reported EPS of $0.01 on revenue of $43.3M, with revenue down 9.6% from a year ago. Over its last 8 reports the stock moved an average of 15.4% the session after earnings. Over the last 12 months BTMD insiders bought $202K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is BTMD in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BTMD.

Key Stats

Last 12 months
Results
Revenue
$178.9M
−8.6% vs a year ago
Net income
−$1.9M
−106.7% vs a year ago
EPS (diluted)
−$0.07
−108.9% vs a year ago
Free cash flow
$7.4M
4.1% margin
Balance sheet
Cash & equivalents
$8.9M
At Sep 30
Debt
$124.2M
At Sep 30
Shareholder equity
−$65.3M
Buybacks
$7.2M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $139.4M$139.4MFY2021FY2022: $165.0M$165.0MFY2022FY2023: $185.4M$185.4MFY2023FY2024: $197.2M$197.2MFY2024FY2025: $192.2M$192.2MFY2025

From BTMD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Mar 10
Estimated date · After the close
Reported EPS
$0.01
Quarter ended Sep 2026
Year ago EPS
$0.22
−95.5% on a GAAP basis
Revenue
$43.3M
−9.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.11Dec '24Mar 2025: $0.37Mar '25Jun 2025: $0.10Jun '25Sep 2025: $0.22Sep '25Dec 2025: $0.06Dec '25Mar 2026: $0.06Mar '26Jun 2026: -$0.23Jun '26Sep 2026: $0.01Sep '26Latest $0.01
Revenue by quarter
Dec 2024: $49.8MDec '24Mar 2025: $49.0MMar '25Jun 2025: $48.9MJun '25Sep 2025: $48.0MSep '25Dec 2025: $46.4MDec '25Mar 2026: $44.9MMar '26Jun 2026: $44.2MJun '26Sep 2026: $43.3MSep '26Latest $43.3M
How BTMD moved after its last 8 reports
Average move the session after a report ±15.4%
Nov 4, 2026After the close−15.4%
Aug 5, 2026After the close−27.9%
May 6, 2026After the close−5.0%
Mar 11, 2026After the close−10.5%
Nov 5, 2025After the close−3.1%
Aug 6, 2025After the close−24.4%
May 7, 2025After the close+12.0%
Mar 12, 2025After the close−25.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on BTMDStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on BTMD
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on BTMD

Technical Analysis

BTMD · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 30% below its 20 day and 40% below its 50 day average. It is 114% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), near oversold. The nearest support is the 52 week low at $0.81, and the nearest resistance the Pivot at $0.82.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 11.2%/day
Key levels
$2.9052 week high+258.0%
$1.74200 day average+114.8%
$1.51100 day average+86.4%
$1.24Swing high (Nov 4)+53.1%
$1.1450 day average+40.7%
$1.0620 day average+30.9%
$0.84Pivot R1+3.7%
$0.82Pivot+1.2%
$0.8152 week low+0.0%
$0.81Last close
$0.80Pivot S1−1.2%
Indicators
RSI (14)31.38Weak, oversold below 30Neutral
MACD-0.08Below its signal lineBearish
Stochastic2.1Near the bottom of its rangeOversold
ADX (14)24.9Weak trend
Williams %R-98.9Oversold below −80, overbought above −20Oversold
CCI (20)-202.4Oversold below −100, overbought above 100Oversold
Rate of change−23.1%Change over 10 sessionsBearish
ATR (14)$0.09Typical daily range, 11.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BTMD

What happened before

See how BTMD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow BTMD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How BTMD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for BTMDHow many large options trades hit BTMD, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

BTMD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼10 buying vs 57 selling
  • ▼Shares held by funds -24.9%
  • ▼Funds holding -15
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding5772−20.8%
In funds' top 10110.0%
Held by funds–––
New / increased7 / 315 / 25−75.0%
Reduced / sold out35 / 2220 / 26+23.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BTMD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

BTMD Insider Trading

All filings →
Insider trading · 12 months
Insiders are buying
Bought$202K1 buy · 1 insider
Sold$00 sales · 0 insiders
2026-08 bought $202KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 11Marc D BeerExecutive ChairmanBuy131,950$1.53$202K
May 7, 2025Richard R Barrera10% ownerBuy447,714$3.26$1.5M
Apr 30, 2025RB Management GP LLC10% ownerBuy1,933$3.30$6K
Apr 21, 2025Richard R Barrera10% ownerBuy8,801$3.27$29K
Apr 17, 2025Guines LLC10% ownerBuy7,874$3.29$26K
Apr 9, 2025Guines LLC10% ownerBuy48,439$3.21$155K
Every insider buy and sale for BTMD over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See BTMD insider trades →

From SEC Form 4 filings by BTMD's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BTMD is in one of them and how their past BTMD trades turned out.

BTMD in the AI portfolios
Loading…

BTMD News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BTMD in an article yet. Here's the latest on the wider market.

BTMD in the news

About biote

biote is based in Irving, Texas, and runs a practice-building platform for clinics that treat hormone imbalance. The platform gives certified practitioners training, certification, practice management and inventory software, and marketing support. Clinics pay fees for the program, and biote also sells its own line of dietary supplements through the same practitioner network. Its customers are mainly physicians and clinics focused on treating symptoms of menopause and male hormone decline.

Headquarters
Irving, TX